Navigation Links
Avoid unnecessary screening tests for celiac disease in the absence of symptoms in children with Downs syndrome

Indianapolis – Children with Downs Syndrome when subjected to any of the regular screening tests for celiac disease , even when they are not exhibiting any symptoms of the disease // , is certainly not the done thing, as it may cause more harm than good according to a study by Indiana University School of Medicine researchers published in the August issue of Pediatrics.

"Although there are tests to find out whether a child with Down syndrome has celiac disease before the child develops symptoms, early treatment does not appear to improve the child's quality of life or improve outcomes from one of the long-term consequences of celiac disease, non-Hodgkin's lymphoma," said Nancy Swigonski, M.D., M.P.H., the study's first author and an associate professor of pediatrics at the Indiana University School of Medicine and affiliated scientist of the Regenstrief Institute, Inc. Celiac disease is a genetic autoimmune disorder that damages the small intestine and interferes with absorption of nutrients from food. Individuals with celiac disease cannot tolerate gluten, a protein found in wheat, rye, and barley. Untreated celiac disease is thought to increase the risk of intestinal lymphoma.

Using decision analysis, a tool for weighing alternative courses of action in terms of their potential benefits and liabilities, the researchers looked at the potential benefit of preventing gastrointestinal malignancy by detecting celiac disease in children without symptoms of the disease and weighed the benefit against the cost and quality of life issues associated with screening and treatment of celiac disease. They also calculated the number of asymptomatic children with Down syndrome who needed to be screened to prevent a single case of lymphoma.

The researchers report that routine screening of all children with Down syndrome would cost $500,000 per life-year gained and that screening all asymptomatic children with Down syndrome for celiac disease would cost
'"/>




Page: 1 2

Related medicine news :

1. Avoid sudden death by quick cooling
2. Avoid stress to have strong babies
3. Avoid travel to Toronto - WHO
4. Risky Drugs To Be Avoided In The Elderly
5. Avoiding Drugs During Pregnancy
6. Avoid Coffee Before Undergoing PET/ CT scans
7. Top Ten Super Food Items That Can Help In Avoiding Cancer
8. Top Ten Super Food Items That Can Help In Avoiding Cancer
9. Smokers Avoid Dental Care More Than Others
10. Combination Therapy To Avoid Prostate Cancer Recurrence
11. Another Feather In The Garlic Cap: Helpful In Avoiding Breast Cancer
Post Your Comments:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 1NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 2NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement 6214 3Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 1Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 2Mithridion Announces Progress With Drugs for Alzheimers Disease and Schizophrenia 6211 3Gene Therapy Brings New Muscle to Monkeys 61251 1
Other Medicine Technology:Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 2Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 3Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 4Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 5Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO 6